The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2020 | TOURMALINE-AL1: ixazomib and dexamethasone for AL amyloidosis
Giampaolo Merlini
• 24 Sep 2020
Giampaolo Merlini, MD, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy, discusses the Phase III TOURMALINE-AL1 trial (NCT01659658), a study that compares the efficacy of ixazomib and dexamethasone versus physician’s choice in relapsed or refractory systemic light-chain (AL) amyloidosis patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
